Author/Authors :
Mark E. Salvati، نويسنده , , Aaron Balog، نويسنده , , Weifang Shan، نويسنده , , Donna D. Wei، نويسنده , , Dacia Pickering، نويسنده , , Ricardo M. Attar، نويسنده , , Jieping Geng، نويسنده , , Cheryl A. Rizzo، نويسنده , , Marco M. Gottardis، نويسنده , , Roberto Weinmann، نويسنده , , Stanley R. Krystek، نويسنده , , John Sack، نويسنده , , Yongmi An، نويسنده , , Kevin Kish، نويسنده ,
Abstract :
A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule.
Keywords :
androgen receptor , prostate cancer , crystal structure , Antagonists